Results 101 to 110 of about 17,302 (216)

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

open access: yesMolecular Oncology, Volume 20, Issue 11, Page 2569-2583, November 2026.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary   +1 more
wiley   +1 more source

Venetoclax with low-dose cytarabine, a forgotten combination in patients with acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review

open access: yesHematology, Transfusion and Cell Therapy
Background: Based on the VIALE-A and VIALE-C studies, the Food and Drug Administration approved venetoclax in 2020 in combination with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia ineligible for intensive ...
Lauro Fabián Amador-Medina   +3 more
doaj   +1 more source

Azacitidine-induced acute lung injury in a patient with therapy-related myelodysplastic syndrome

open access: yes, 2017
Azacitidine is a first-in-class demethylating agent, and it is widely used globally as a first-line treatment for higher-risk myelodysplastic syndrome (MDS). Here, we report the case of a patient with MDS who suffered from a rare adverse event, an acute
Akiko Miyagi Maeshima   +10 more
core   +1 more source

PANoptosis in the pathogenesis of myelodysplastic syndromes

open access: yesMolecular Oncology, Volume 20, Issue 11, Page 2584-2610, November 2026.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla   +4 more
wiley   +1 more source

Two Blastic Plasmacytoid Dendritic Cell Neoplasms treated with the CD123‐targeted agent Tagraxofusp presenting divergent outcomes

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Sven C. Engler   +4 more
wiley   +1 more source

GATA2 Deficiency Presenting With a WHIM‐Like Phenotype and Subsequent Development of Monosomy 7‐Associated Myelodysplastic Syndrome in an Adolescent Female: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 11, November 2026.
ABSTRACT We report an 18‐year‐old female with GATA2 deficiency presenting with a WHIM‐like phenotype, including pancytopenia, monocytopenia, CD19+ B‐cell depletion, sensorineural hearing loss, and cutaneous warts. Subsequent cytogenetic evaluation revealed monosomy 7 and 7q22 deletion, with bone marrow progression to MDS.
Aziz Eghbali   +2 more
wiley   +1 more source

Clinical Analysis of Venetoclax Combined with Azacitidinein Hig-risk Myelodysplastic Syndrome

open access: yesGuoji laonian yixue zazhi
Objective To investigate the efficacy and safety of Venetoclax combined with Azacitidine in the treatment of high-risk myelodysplastic syndrome. Methods A total of 56 patients with high-risk myelodysplastic syndrome were enrolled from June 2019 to June ...
Tianjiao Huang   +8 more
doaj   +1 more source

Remission of relapsing polychondritis after successful treatment of myelodysplastic syndrome with azacitidine: a case and review of the literature

open access: yes, 2018
Background: Relapsing polychondritis (RP) is a rare autoimmune disorder, and myelodysplastic syndrome (MDS) is accompanied by RP at variable rates. Herein, we report a case with RP and MDS who responded dramatically to 5-azacitidine for MDS.
ERDEN, ABDULSAMET   +13 more
core   +1 more source

Eltrombopag during induction chemotherapy in older patients with newly diagnosed acute myeloid leukemia is safe and reduces platelet transfusion requirements: The EPAG‐2015 French Innovative Leukemia Organization phase 2 randomized trial

open access: yesCancer, Volume 132, Issue 21, 1 November 2026.
Abstract Background Elderly patients with acute myeloid leukemia (AML) treated with intensive chemotherapy are at risk of developing thrombopenia, which requires platelet transfusions. It would be interesting to provide them with thrombopoietin receptor agonists such as eltrombopag.
Arnaud Pigneux   +24 more
wiley   +1 more source

Acute Myeloid Leukemia With KAT6A::CREBBP Rearrangement: A Rare Entity With Potential Diagnostic Pitfalls

open access: yes
International Journal of Laboratory Hematology, EarlyView.
Adam Lyle   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy